Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Profound Research LLC

Neither a doctor nor a teaching hospital

Research payments

$5,905,182

1,322 payments

Through program year 2025, Profound Research LLC is reported as receiving $5,905,182 in research payments, across 1,322 payments.

By program year

2 rows
Year Kind Amount Payments
2025 Research $3,812,582 843
2024 Research $2,092,601 479

Breakdown

Who paid Research payments · program years 2024–2025
  1. Eli Lilly and Company $1,620,305 9 payments
  2. Regeneron Pharmaceuticals, Inc. $935,663 778 payments
  3. Merck Sharp & Dohme Corporation $617,382 9 payments
  4. AbbVie, Inc. $612,775 99 payments
  5. Genzyme Corporation $412,291 88 payments
  6. AstraZeneca Pharmaceuticals LP $378,038 8 payments
  7. Janssen Research & Development, LLC $184,103 46 payments
  8. AstraZeneca UK Limited $174,098 3 payments
  9. Pfizer Inc. $140,008 83 payments
  10. H. Lundbeck A S $133,833 14 payments
Studies the money was for Research payments · program years 2024–2025
  1. Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $829,677 2 payments
  2. A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome $494,481 181 payments
  3. A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants $451,600 61 payments
  4. A Randomized, Double-Blinded Study to Evaluate the Efficacy and Safety of Mevidalen in Patients With Alzheimer's Disease $413,131 3 payments
  5. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $349,547 2 payments
  6. Assessment of Hemodynamics, Symptomatology, and Biochemical markers of NPR1 Signaling in Healthy Volunteers and Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Patients with Neurogenic Orthostatic Hypotension (nOH) $301,383 553 payments
  7. Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis $197,806 44 payments
  8. A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic NSCLC With High PD-L1 Expression and Without Actionable Genomic Alterations (TROPION-Lung10) $196,390 2 payments
  9. A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab MK-3475 Versus Treatment of Physician s Choice TPC in Participants With Triple-Negative Breast Cancer TNBC Who Received $169,335 2 payments
  10. An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab MK-3475 in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than $154,469 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record